Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
نویسندگان
چکیده
Several large intervention trials have investigated the potential of fibrates to reduce cardiovascular events. The results have varied widely: positive, with gemfibrozil in the primary prevention Helsinki Heart Study (HHS)1 and the secondary prevention Veterans Administration High Density Lipoprotein Intervention Trial (VA-HIT)2; positive, with reservations related to an increase in noncardiovascular mortality in the primary prevention World Health Organization trial (clofibrate)3; and mixed, with bezafibrate in the secondary prevention Bezafibrate Infarction Prevention (BIP) study4 and with fenofibrate in the combined primary and secondary prevention FIELD study,5 in which positive outcomes were observed only in certain subgroups. Reasons for the differences between the outcomes of these studies are not immediately apparent.
منابع مشابه
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
Thiazolidinediones (TZDs) are insulin sensitizers widely used in the treatment of type 2 diabetes (1). Fibrates are lipid-lowering drugs that lower triglycerides (TGs) and increase HDL cholesterol (2). Individually, fibrates and TZDs generally raise HDL cholesterol. In this study, we report that certain patients treated with a combination of fibrates (fenofibrate) and a TZD (rosiglitazone) show...
متن کاملEffect of fibrate treatment on liver function tests in patients with the metabolic syndrome
BACKGROUND Fibrates are used especially in patients with hypertriglyceridaemia, a feature of the metabolic syndrome. Elevated LFTs are often observed in these patients perhaps related to fatty infiltration. AIM We wished to study changes seen in LFTs (GGT, ALT and ALP) following fibrate therapy and then determine associated factors. METHODS This was a retrospective observational study in wh...
متن کاملA Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates
There are no data on the incidence of new-onset diabetes mellitus (NODM ) in nondiabetic dyslipidaemia patients treated with fibrates. The aim of our study was to clarify these issues, to investigate the relationship between NODM and fibrate and whether the fibrates lead to increased risk for developing NODM. A retrospective cohort study was conducted by analyzing the Longitudinal Health Insura...
متن کاملA nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion.
Fibrates are commonly used lipid-lowering agents that act via PPARalpha, a member of the nuclear hormone receptor superfamily. The mechanism(s) of fibrate-induced changes in the hepatic canalicular membrane and bile lipids are still unknown. Therefore, the aim of this study was to investigate the influence of fibrates on hepatic lipid metabolism and to assess the hepatocellular cytoprotective e...
متن کاملUse of fibrates in the United States and Canada.
CONTEXT Interest in the role of fibrates intensified after the publication of the negative results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which assessed therapy with fenofibrate plus statins. The evidence for clinical benefit in outcomes with the use of fibrates is heavily weighted on the use of the older fibrates such as gemfibrozil and clofibrate. OBJECTI...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation
دوره 113 12 شماره
صفحات -
تاریخ انتشار 2006